Drug
Cosibelimab
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
2
50%
Ph phase_4
1
25%
Phase Distribution
2
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Terminated(2)
Detailed Status
Terminated2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
terminated250%
not_yet_recruiting250%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_4
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT07426484
not_yet_recruitingphase_1
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
NCT06981806
terminatedphase_3
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
NCT04786964
terminatedphase_1
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
NCT03778073
Clinical Trials (4)
Showing 4 of 4 trials
NCT07426484Phase 4
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT06981806Phase 1
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
NCT04786964Phase 3
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
NCT03778073Phase 1
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4